PSL3 overexpression has been shown to improve the clinical phenotype both in animal models of SMA (49) and in human patients (50), with subjects coming from the same family and having the same SMN2 copy number presenting with variable severity according to PSL3 serum levels. The gene discussed is SMN2; the disease is proximal spinal muscular atrophy.